NeuroSense Therapeutics (NRSN) April 2024 Investor Presentation

Loading viewer...

investor_presentation

Format: PDF investor_presentation

NeuroSense Therapeutics is developing novel therapies for neurodegenerative diseases including ALS (amyotrophic lateral sclerosis). The company presented significant top-line results from its Phase 2b clinical trial, with biomarker results expected in H1 2024 and an expedited regulatory pathway under orphan drug designation.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

Similar investor_presentations from other companies

Browse all →

Pure Storage Investor Presentation — February 2021

investor_presentation

15 Pages

Pure Storage